Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview

23847studies shown

Showing 20,929-20,940 of 23,847

Drug study icon

CompletedNCT00097266

Aripiprazole in people with Acute Bipolar Mania

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Anaheim

BipolarityDrugOver 18 Years

Countries: United States, Bulgaria, Croatia, ...
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Bipolarity

Drug study icon

CompletedNCT00257972

Aripiprazole in people with Bipolarity type I

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Little Rock

BipolarityDrugOver 18 Years

Countries: United States, Australia, France, ...
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Bipolarity

Drug study icon

CompletedNCT00080314

Aripiprazole in people with Bipolarity type I With a Major Depression Episode

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Tuscaloosa

Bipolarity, DepressionDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Bipolarity, Depression

Drug study icon

CompletedNCT00392197

Aripiprazole in people with Schizophrenia- Effects on Glucose Metabolism-

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Hokkaido Region

SchizophreniaDrugOver 16 Years

Countries: Japan
Sponsor: Otsuka Pharmaceutical Co., Ltd.
Condition: Schizophrenia

Drug study icon

CompletedNCT00036101

Aripiprazole in the Treatment of people with Acute Symptoms in Bipolarity

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Tuscaloosa

BipolarityDrugOver 18 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Bipolarity

Drug study icon

CompletedNCT00046384

Aripiprazole in the Treatment of people with Acute Symptoms of Bipolarity

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Scottsdale

BipolarityDrugOver 18 Years

Countries: United States, Argentina
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Bipolarity

Drug study icon

CompletedNCT00036114

Aripiprazole in the Treatment of people with Psychosis Associated With Dementia of the Alzheimer's Type

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Tuscaloosa

SchizophreniaDrugFrom 55 Years to 95 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

Drug study icon

TerminatedNCT00665444

Aripiprazole to Reduce Medical Risks in Bipolarity

This study exists to see whether the medication Aripiprazole can make care clearer and more responsive. Researchers are trying to understand whether the medication Aripiprazole can give earlier or clearer feedback during care.

In Pittsburgh

BipolarityDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: University of Pittsburgh
Condition: Bipolarity

Drug study icon

CompletedNCT00281320

Asenapine in Elderly Subjects With Psychosis (A7501021)(P05717)

This study exists to better understand the safety of the medication Asenapine and how manageable it feels in practice. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.

Location not clearly listed

SchizophreniaDrugOver 65 Years

Countries
Sponsor: Organon and Co
Condition: Schizophrenia

Drug study icon

CompletedNCT00585910

Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD

This summary needs review. Please check the official study record and contact the research team for details.

In Cambridge

ADHDDrugFrom 6 Years to 17 Years

Countries: United States
Sponsor: Massachusetts General Hospital
Condition: ADHD

Drug study icon

CompletedNCT00191633

Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Calgary

ADHDDrugFrom 6 Years to 11 Years

Countries: Canada
Sponsor: Eli Lilly and Company
Condition: ADHD

Other study type icon

CompletedEUCTR 2018-003271-35

ATTENTION AND IMPULSIVITY IN HEALTHY HUMAN VOLUNTEERS

This summary needs review. Please check the official study record and contact the research team for details.

In Denmark

ADHDOther

Countries: Denmark
Sponsor: University of Copenhagen
Condition: ADHD

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.